Viswa Colluru

We’re thrilled to announce $130M in Series C funding led by @KinnevikAB and FPV, with participation from @BaillieGifford , @premjiinvest , @Lux_Capital , @trueventures , and many more new and existing partners. With this new capital, we plan to advance multiple drug candidates through Phase 1/2 clinical trials. In just 4 short years since our seed round, we’ve gone from a concept to a clinical-stage company with a deep pipeline of 10 development candidates. 🚀 Thanks to the hard work of our team and the power of our platform, we’re delivering drug candidates 4x faster than industry average—a testament to our thesis, technology, and team. This marks a significant step forward in our journey to transform the future of drug discovery. A heartfelt thank you to our investors, partners, and, most importantly, our talented team for making this possible. Here’s to the next chapter of growth, discovery, and development! 💊💡 Learn more here: tinyurl.com/545v3bwu Read our feature in @Bloomberg here: tinyurl.com/yj4e8j8f

Exclusive: Enveda's first clinical readout shows early promise for its lead eczema drug I talked with @viswacolluru on the ENV-294 data and next steps, including a Phase 2a readout expected in 2H26: endpoints.news/envedas-first-…

Six years ago, this was a thesis. Today, it’s clinical data. Next week at #JPM26, we’ll be sharing progress that reflects years of deliberate choices coming together. Our oral therapy for atopic dermatitis, ENV-294, has generated compelling Phase 1b data showing strong clinical activity and a clean safety profile in one of the largest and most competitive categories in medicine. The signal supports best-in-disease potential and represents exciting clinical proof of the thesis Enveda was built on. ENV-294 matters not just because it is a strong program, but because it is the output of a system we have been building since day one. A company singularly focused on discovering, developing, and delivering breakthrough medicines with the potential to not just capture, but create markets. We now have three assets in the clinic: ENV-294 in atopic dermatitis and asthma, now in Phase 2a with a Jak-like efficacy and a Dupi-like safety profile ENV-308 for obesity, with the first patient dosed in Phase 1, a “statin for obesity”, engineered for a post-GLP1 world ENV-6946 for IBD, bringing together clinically validated biology across TNFa, TL1A, IL23, and NLRP3, via a single novel-target delivered in a convenient pill With additional INDs expected in 2026, Enveda is now a multi-asset clinical-stage company with a highly concentrated set of upcoming catalysts. Looking ahead over the next several quarters, this foundation provides both momentum and resilience. It positions us to move quickly, take meaningful swings, and continue building a generational company that endures. We look forward to sharing more next week in San Francisco. #JPM26 #ENV294 #ENV308 #DrugDiscovery #ClinicalTrials #Biotech #Enveda #LearningFromLife #RevolutionizingImmunology #RevolutionizingObesity

One more thing. We have received another FDA IND clearance and have initiated Phase 1 for ENV-6946, bringing our total to three first-in-class, novel, nature-inspired molecules in the clinic. ENV-6946 is an oral small molecule engineered for the potential to treat inflammatory bowel disease, designed as a “multi-biologic in a pill.” It simultaneously targets TNFα, IL-23, and TL1A signaling in the gut without requiring separate injectable therapies. Millions of people live with IBD, with far too few efficacious, safe, durable, and convenient options available. ENV-6946 represents a new path forward – one designed for efficacy, safety, and simplicity. With ENV-294, ENV-308, and now ENV-6946 in clinical development, we continue to demonstrate: • The ingenuity of nature • The power of our platform • The pace and commitment of our team Onward. Read more: tinyurl.com/345jenj3

One more thing. We have received another FDA IND clearance and have initiated Phase 1 for ENV-6946, bringing our total to three first-in-class, novel, nature-inspired molecules in the clinic. ENV-6946 is an oral small molecule engineered for the potential to treat inflammatory bowel disease, designed as a “multi-biologic in a pill.” It simultaneously targets TNFα, IL-23, and TL1A signaling in the gut without requiring separate injectable therapies. Millions of people live with IBD, with far too few efficacious, safe, durable, and convenient options available. ENV-6946 represents a new path forward – one designed for efficacy, safety, and simplicity. With ENV-294, ENV-308, and now ENV-6946 in clinical development, we continue to demonstrate: • The ingenuity of nature • The power of our platform • The pace and commitment of our team Onward. Read more: tinyurl.com/345jenj3

We are excited to welcome Nadeem Sarwar to Enveda as SVP & Global Head of Disease Prevention and Metabolic Disease Strategy. Nadeem brings rare experience from the front lines of metabolic medicine, as the former Co-Founder and Head of the Transformational Prevention Unit (TPU) at @novonordisk , where he helped shape the industry's approach to obesity, risk, and long-term health. At Enveda, we believe the future of medicine is not just treating disease, but ensuring long-term benefit or even preventing it before it takes hold. With our first-in-class oral metabolic program now in the clinic, Nadeem will help unlock the next chapter: medicines designed for durability, scalability, and real-world use. This isn’t just about doing things differently. It’s about raising the bar for what patients can expect. We are thrilled to help build a healthier future for society. Welcome to Enveda, Nadeem. Read more: tinyurl.com/835rd7jc

Delivering on our promise… We started with a simple thesis: nature has given us history’s best medicines, and with the right technology, we can find, understand, and develop the next generation of breakthroughs. This week, our thesis turned into real clinical momentum. - We obtained compelling interim Phase 1b data in atopic dermatitis, showing robust activity and a clean safety profile. - We initiated parallel Phase 2a studies of ENV-294 for atopic dermatitis and asthma, our first-in-class oral small molecule for inflammatory disease. Running two Phase 2a trials accelerates how quickly we can validate the breadth of ENV-294’s “pipeline-in-a-product” potential across inflammatory biology. And we’re not slowing down: A global Phase 2b dose-ranging is targeted to begin in 2026 to accelerate the development path. This is the kind of velocity we built Enveda to deliver. We are just getting started. See here for more information: tinyurl.com/2ev2b3ps

1/ We started as underdogs. Today, we’re scaling a unicorn. Thrilled to share that @EnvedaBio has raised a $150M Series D, bringing our total funding to over $500M. Led by the incredible team at @PremjiInvest and joined by both new and returning believers. 🧵

How we built a unicorn from seed in 5 years… There are no secrets, but purpose, pace, and an incredible team certainly help. “We’re combining ancient ancestral wisdom with the power of nature’s chemistry with modern AI and drug discovery,” Colluru said. “We’re standing on the shoulders of maybe the giant, which is Mother Nature.” Read more by @damiangarde in @business about how we raised our Series D, advanced our lead candidate in atopic dermatitis to Phase 1b, and brought on a pharma legend Mikael Dolsten as we prepare to enter more programs in the clinic this year... and stay tuned for more. #Unicorn #Startups #AI #DrugDiscovery #Nature

How we built a unicorn from seed in 5 years… There are no secrets, but purpose, pace, and an incredible team certainly help. “We’re combining ancient ancestral wisdom with the power of nature’s chemistry with modern AI and drug discovery,” Colluru said. “We’re standing on the shoulders of maybe the giant, which is Mother Nature.” Read more by @damiangarde in @business about how we raised our Series D, advanced our lead candidate in atopic dermatitis to Phase 1b, and brought on a pharma legend Mikael Dolsten as we prepare to enter more programs in the clinic this year... and stay tuned for more. #Unicorn #Startups #AI #DrugDiscovery #Nature